First-Class Business Newspaper Financial NewsNov 2026
REMEDI’s compact X-ray device has sold over 2,200 units in India, positioning it as a key medical imaging solution. The Indian government has officially designated the product as 'world-class,' recognizing its quality and impact. The device targets healthcare facilities seeking portable and efficient diagnostic tools.
Remedi, a radiation (X-ray) technology company, surged over 30% above its offer price during its first day of trading on the KOSDAQ market. The stock’s strong performance reflects investor confidence in its specialized X-ray technology solutions. The company’s debut marks its entry into the public market with a focus on advanced radiation-based innovations.
Medical device company **Remedi** debuts on the KOSDAQ exchange. Separately, **HLGnomics**, an active pharmaceutical ingredient (API) manufacturer, begins its IPO subscription for retail investors.
Remedi reports accelerating earnings driven by rising demand for its portable X-ray generators in international markets, particularly India. The company’s overseas expansion fuels revenue growth as healthcare facilities adopt its compact imaging solutions. Analysts project continued momentum from export-driven sales.
Remedi is expanding its AI-driven X-ray technology beyond medical applications into industrial nondestructive testing (NDT) and space sectors. The company uses its KOSDAQ listing to accelerate global market entry and strengthen its AI-based X-ray platform. Remedi’s core offerings include portable medical X-ray equipment and key components for industrial applications.
Remedi, a Korean small and medium-sized enterprise (SME), delivers an ultra-compact X-ray device to NASA, securing the contract over competitors from the U.S. and Japan. The device targets advanced imaging applications in space exploration. Remedi’s innovation aligns with Korea’s procurement-backed initiatives to foster domestic tech development.